– USA, GA – Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide today announced the appointment of Board member Charlie Larsen to the role of non-executive Chair, replacing founder, president, and CEO, Kathy Lee-Sepsick.
Mr. Larsen has served as a member of Femasys’ board of directors since October 2015.
“Charlie’s extensive experience in the medical device industry, executive leadership and experience in strategic transformations, along with his public board experience will provide important insight as we plan to make our novel biomedical solutions available to women worldwide, in support of our mission to change women’s health.” said founder and CEO, Kathy Lee-Sepsick.
About Charles Larsen
Mr. Larsen co-founded Novoste Corporation in 1992 and The Innovation Factory in 1999, and, through his role at The Innovation Factory, he co-founded additional companies including medical device companies such as Acufocus, Inc., AqueSys Inc., Halscion, Inc., Neuronetics, Inc. and Sebacia, Inc. He holds over 30 issued U.S. and international patents on medical devices. Before joining Novoste, Mr. Larsen held positions with Novoste Puerto Rico, Cordis Corporation, Key Pharmaceuticals, and Parke-Davis/Warner-Lambert in executive, senior engineering, and project management roles. Mr. Larsen also served on the Board of Directors of Acufocus, CardioFocus, Inogen Inc, Intuity Medical Inc., Novoste Inc., and Torax Medical, Inc.
Mr. Larsen, said, “I have spent the entirety of the past 40 years of my career developing medical technologies to address areas of unmet need and improve patient outcomes and I am excited for this opportunity to serve as Chair of the Board. I look forward to working with Kathy Lee-Sepsick, the board, and the broader team to continue the development of its lead product candidates, FemaSeed and FemBloc, and preparations for the commercial launch of FemCerv.”
Mr. Larsen holds a BS in Mechanical Engineering from the New Jersey Institute of Technology.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc permanent birth control and FemaSeed localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue, is currently marketed in the United States. Femasys is also advancing FemCath, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
For more information: https://www.femasys.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
